For illustration purposes only | |
Medical intervention | Incremental cost-effectiveness ratio ($ per discounted quality-adjusted life year gained unless indicated otherwise) |
No prophylaxis versus intravenous saline for prevention of contrast-induced nephropathy in high risk patients[1] | No prophylaxis is cost-saving |
Publicly funded opiate use disorder treatment versus standard care[2] | Cost-saving |
Individualized glycemic control versus uniform control[3] | Cost-saving |
Novel oral anticoagulant versus warfarin[4] | Cost-saving to $2073 (assuming £1 = $1.4) |
Achieving UNAIDS 90-90-90 global HIV treatment target aims in South Africa over 10 years[5] | $1260 per life year gained |
Statin therapy for 1-year risk threshold of 7.5% versus 10% for primary prevention of cardiovascular disease[6] | $37,000 |
Intensive versus standard blood pressure control in Systolic Blood Pressure Intervention Trial (SPRINT)[7] | $47,000 |
Risk-targeted low-dose CT versus NLST screening[8] | $53,000 to $75,000 |
Statin-plus-PCSK9 inhibitor versus statin-plus-ezetimibe for atherosclerotic cardiovascular disease and LDL-C ≥70 mg/mL[9] | $450,000 |
Initial biologic therapy versus triple therapy for active rheumatoid arthritis[10] | $521,520 |
Do you want to add Medilib to your home screen?